Kazuaki Kakehi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kazuaki Kakehi has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Mitsuhiro Kinoshita
School of Pharmacy, Kindai University, Higashi-Osaka, Osaka, Japan
30 shared publicationsYasuo Oda
12 shared publicationsTakao Hayakawa
Pharmaceutical Research and Technology Institute, Kinki University, Kowakae 3-4-1, Higashi-Osaka 577-8502, Japan
8 shared publicationsKeita Yamada
School of Pharmacy, Kindai University, Higashi-Osaka, Osaka, Japan
5 shared publicationsTakashi Masuko
Faculty of Pharmaceutical Sciences, Kinki University, Kowakae 3-4-1, Higashi-Osaka 577-8502, Japan
5 shared publicationsYu-Ki Matsuno
4 shared publications
Latest Publications
- 22 March 2017
- Published by Wiley in Electrophoresis
- Vol. 38 (9-10) , 1344-1352
Combination of SDS‐PAGE and intact mass analysis for rapid determination of heterogeneities in monoclonal antibody therapeutics
MAbs are currently mainstream in biopharmaceuticals, and their market has been growing due to their high target specificity. Characterization of heterogeneities in mAbs is performed to secure their quality and safety by physicochemical analyses. However, they require time-consuming task, which often strain the resources of drug development in pharmaceuticals. Rapid and direct method to determine the heterogeneities should be a powerful tool for pharmaceutical analysis. Considering the advantages of electrophoresis and MS, this study addresses the combination of SDS-PAGE and intact mass analysis, which provides direct, rapid, and orthogonal determination of heterogeneities in mAb therapeutics. mAb therapeutics that migrated in SDS-PAGE were recovered from gel by treatment with SDC-containing buffer. Usage of SDC-containing buffer as extraction solvent and ethanol-based staining solution enhanced the recovery of intact IgG from SDS-PAGE gels. Recovery of mAbs reached more than 86% with 0.2% SD. The heterogeneities, especially N-glycan variants in the recovered mAb therapeutics, were clearly determined by intact mass analysis. We believe that the study is important in pharmaceuticals‧ perspective since orthogonal combination of gel electrophoresis and intact mass analysis should be pivotal role for rapid and precise characterization of mAbs.
- 22 March 2017
- Published by Wiley in Electrophoresis
- Vol. 38 (9-10) , 1344-1352
Combination of SDS‐PAGE and intact mass analysis for rapid determination of heterogeneities in monoclonal antibody therapeutics
MAbs are currently mainstream in biopharmaceuticals, and their market has been growing due to their high target specificity. Characterization of heterogeneities in mAbs is performed to secure their quality and safety by physicochemical analyses. However, they require time-consuming task, which often strain the resources of drug development in pharmaceuticals. Rapid and direct method to determine the heterogeneities should be a powerful tool for pharmaceutical analysis. Considering the advantages of electrophoresis and MS, this study addresses the combination of SDS-PAGE and intact mass analysis, which provides direct, rapid, and orthogonal determination of heterogeneities in mAb therapeutics. mAb therapeutics that migrated in SDS-PAGE were recovered from gel by treatment with SDC-containing buffer. Usage of SDC-containing buffer as extraction solvent and ethanol-based staining solution enhanced the recovery of intact IgG from SDS-PAGE gels. Recovery of mAbs reached more than 86% with 0.2% SD. The heterogeneities, especially N-glycan variants in the recovered mAb therapeutics, were clearly determined by intact mass analysis. We believe that the study is important in pharmaceuticals‧ perspective since orthogonal combination of gel electrophoresis and intact mass analysis should be pivotal role for rapid and precise characterization of mAbs.
- 20 October 2014
- Published by Springer Nature
- p. 111-118
Capillary Electrophoresis of Glycans: Validation of Antibody Pharmaceuticals Based on Glycan Profiles
- 20 October 2014
- Published by Springer Nature
- p. 111-118
Capillary Electrophoresis of Glycans: Validation of Antibody Pharmaceuticals Based on Glycan Profiles
- 22 July 2014
- Published by Springer Nature
- Vol. 1200, 131-146
Capillary-Based Lectin Affinity Electrophoresis for Interaction Analysis Between Lectins and Glycans
Capillary affinity electrophoresis (CAE) is a powerful technique for glycan analysis, and one of the analytical approaches for analyzing the interaction between lectins and glycans. The method is based on the high-resolution separation of fluorescently labeled glycans by capillary electrophoresis (CE) with laser-induced fluorescence detection (LIF) in the presence of lectins (or glycan binding proteins). CAE allows simultaneous determination of glycan structures in a complex mixture of glycans. In addition, we can calculate the binding kinetics on a specific glycan in the complex mixture of glycans with a lectin. Here, we show detailed procedures for capillary affinity electrophoresis of fluorescently labeled glycans with lectins using CE-LIF apparatus. Its application to screening a sialic acid binding protein in plant barks is also shown.
- 22 July 2014
- Published by Springer Nature
- Vol. 1200, 131-146
Capillary-Based Lectin Affinity Electrophoresis for Interaction Analysis Between Lectins and Glycans
Capillary affinity electrophoresis (CAE) is a powerful technique for glycan analysis, and one of the analytical approaches for analyzing the interaction between lectins and glycans. The method is based on the high-resolution separation of fluorescently labeled glycans by capillary electrophoresis (CE) with laser-induced fluorescence detection (LIF) in the presence of lectins (or glycan binding proteins). CAE allows simultaneous determination of glycan structures in a complex mixture of glycans. In addition, we can calculate the binding kinetics on a specific glycan in the complex mixture of glycans with a lectin. Here, we show detailed procedures for capillary affinity electrophoresis of fluorescently labeled glycans with lectins using CE-LIF apparatus. Its application to screening a sialic acid binding protein in plant barks is also shown.
- 9 May 2014
- Published by Springer Nature
- p. 1-7
Capillary Electrophoresis of Glycans: Validation of Antibody Pharmaceuticals Based on Glycan Profiles
- 9 May 2014
- Published by Springer Nature
- p. 1-7
Capillary Electrophoresis of Glycans: Validation of Antibody Pharmaceuticals Based on Glycan Profiles
- 26 December 2013
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 13 (2) , 1021-1033
Common Glycoproteins Expressing Polylactosamine-Type Glycans on Matched Patient Primary and Metastatic Melanoma Cells Show Different Glycan Profiles
Recently, we reported comparative analysis of glycoproteins which express cancer-specific N-glycans on various cancer cells and identified 24 glycoproteins having polylactosamine (polyLacNAc)-type N-glycans that are abundantly present in malignant cells [ Mitsui et al., J. Pharm. Biomed. Anal. 2012 , 70 , 718−726]. In the present study, we applied the technique to comparative studies on common glycoproteins present in the matched patient primary and metastatic melanoma cell lines. Metastatic melanoma cells (WM266-4) contained a large amount of polyLacNAc-type N-glycans in comparison with primary melanoma cells (WM115). To identify the glycoproteins expressing these N-glycans, glycopeptides having polyLacNAc-type N-glycans were captured by a Datura stramonium agglutinin (DSA)-immobilized agarose column. The captured glycopeptides were analyzed by LC/MS after removing N-glycans, and some glycoproteins such as basigin, lysosome-associated membrane protein-1 (LAMP-1), and chondroitin sulfate proteoglycan 4 (CSPG4) were identified in both WM115 and WM266-4 cells. The expression level of polyLacNAc of CSPG4 in WM266-4 cells was significantly higher than that in WM115 cells. In addition, sulfation patterns of chondroitin sulfate (CS) chains in CSPG4 showed dramatic changes between these cell lines. These data show that characteristic glycans attached to common proteins observed in different stages of cancer cells will be useful markers for determining degree of malignancies of tumor cells.
- 26 December 2013
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 13 (2) , 1021-1033
Common Glycoproteins Expressing Polylactosamine-Type Glycans on Matched Patient Primary and Metastatic Melanoma Cells Show Different Glycan Profiles
Recently, we reported comparative analysis of glycoproteins which express cancer-specific N-glycans on various cancer cells and identified 24 glycoproteins having polylactosamine (polyLacNAc)-type N-glycans that are abundantly present in malignant cells [ Mitsui et al., J. Pharm. Biomed. Anal. 2012 , 70 , 718−726]. In the present study, we applied the technique to comparative studies on common glycoproteins present in the matched patient primary and metastatic melanoma cell lines. Metastatic melanoma cells (WM266-4) contained a large amount of polyLacNAc-type N-glycans in comparison with primary melanoma cells (WM115). To identify the glycoproteins expressing these N-glycans, glycopeptides having polyLacNAc-type N-glycans were captured by a Datura stramonium agglutinin (DSA)-immobilized agarose column. The captured glycopeptides were analyzed by LC/MS after removing N-glycans, and some glycoproteins such as basigin, lysosome-associated membrane protein-1 (LAMP-1), and chondroitin sulfate proteoglycan 4 (CSPG4) were identified in both WM115 and WM266-4 cells. The expression level of polyLacNAc of CSPG4 in WM266-4 cells was significantly higher than that in WM115 cells. In addition, sulfation patterns of chondroitin sulfate (CS) chains in CSPG4 showed dramatic changes between these cell lines. These data show that characteristic glycans attached to common proteins observed in different stages of cancer cells will be useful markers for determining degree of malignancies of tumor cells.
- 24 February 2012
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 84 (5) , 2373-2379
Analysis of Nonhuman N-Glycans as the Minor Constituents in Recombinant Monoclonal Antibody Pharmaceuticals
Minor N-linked glycans containing N-glycolylneuraminic acid residues and/or α-Gal epitopes (i.e., galactose-α1,3-galactose residues) have been reported to be present in recombinant monoclonal antibody (mAb) therapeutics. These contaminations are due to their production processes using nonhuman mammalian cell lines in culture media containing animal-derived materials. In case of the treatment of tumors, we inevitably use such mAbs by careful risk–benefit considerations to prolong patients’ lives. However, expanding their clinical applications such as for rheumatism, asthma, and analgesia demands more careful evaluation of the product characteristics. The present work for detailed evaluations of N-glycans demonstrates the methods using capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) and a combination of high-performance liquid chromatography and electrospray ionization time-of-flight mass spectrometry. The CE-LIF method provides excellent separation of both major and minor N-glycans from six commercial mAb pharmaceuticals within 30 min and clearly indicates that a possible trigger of immunogenicity in humans due to the presence of nonhuman N-glycans is present. We strongly believe that the proposed method will be a powerful tool for the analysis of N-glycans of recombinant mAb products in various development stages, such as clone selection, process control, and routine release testing to ensure safety and efficacy of the products.
- 24 February 2012
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 84 (5) , 2373-2379
Analysis of Nonhuman N-Glycans as the Minor Constituents in Recombinant Monoclonal Antibody Pharmaceuticals
Minor N-linked glycans containing N-glycolylneuraminic acid residues and/or α-Gal epitopes (i.e., galactose-α1,3-galactose residues) have been reported to be present in recombinant monoclonal antibody (mAb) therapeutics. These contaminations are due to their production processes using nonhuman mammalian cell lines in culture media containing animal-derived materials. In case of the treatment of tumors, we inevitably use such mAbs by careful risk–benefit considerations to prolong patients’ lives. However, expanding their clinical applications such as for rheumatism, asthma, and analgesia demands more careful evaluation of the product characteristics. The present work for detailed evaluations of N-glycans demonstrates the methods using capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) and a combination of high-performance liquid chromatography and electrospray ionization time-of-flight mass spectrometry. The CE-LIF method provides excellent separation of both major and minor N-glycans from six commercial mAb pharmaceuticals within 30 min and clearly indicates that a possible trigger of immunogenicity in humans due to the presence of nonhuman N-glycans is present. We strongly believe that the proposed method will be a powerful tool for the analysis of N-glycans of recombinant mAb products in various development stages, such as clone selection, process control, and routine release testing to ensure safety and efficacy of the products.
- 5 April 2011
- Published by Wiley in Biomedical Chromatography
- Vol. 25 (5) , 588-593
Determination of sulfate ester content in sulfated oligo‐ and poly‐saccharides by capillary electrophoresis with indirect UV detection
Carbohydrates having sulfate groups such as glycosaminoglycans and chemically synthesized sucrose sulfate show interesting and important biological activities. We adapted CE with indirect UV detection technique to the determination of sulfate ester in sulfated carbohydrates, which were previously hydrolyzed with HCl. The liberated sulfate ion was analyzed using a background electrolyte consisting of triethanolamine‐buffered chromate with hexamethonium bromide. Sulfate contents of glucose 3‐sulfate and sucrose octasulfate used as a model were in good agreement with theoretical values (accuracy, 95.9–96.7 and 97.4–101.9%, respectively), and relative standard deviation values run‐to‐run were 0.977 and 1.90%, respectively. We applied the method to the determination of the sulfate contents of some glycosaminoglycan samples and showed that the contents were in good agreement with those calculated from sulfur content. Copyright © 2010 John Wiley & Sons, Ltd.
- 5 April 2011
- Published by Wiley in Biomedical Chromatography
- Vol. 25 (5) , 588-593
Determination of sulfate ester content in sulfated oligo‐ and poly‐saccharides by capillary electrophoresis with indirect UV detection
Carbohydrates having sulfate groups such as glycosaminoglycans and chemically synthesized sucrose sulfate show interesting and important biological activities. We adapted CE with indirect UV detection technique to the determination of sulfate ester in sulfated carbohydrates, which were previously hydrolyzed with HCl. The liberated sulfate ion was analyzed using a background electrolyte consisting of triethanolamine‐buffered chromate with hexamethonium bromide. Sulfate contents of glucose 3‐sulfate and sucrose octasulfate used as a model were in good agreement with theoretical values (accuracy, 95.9–96.7 and 97.4–101.9%, respectively), and relative standard deviation values run‐to‐run were 0.977 and 1.90%, respectively. We applied the method to the determination of the sulfate contents of some glycosaminoglycan samples and showed that the contents were in good agreement with those calculated from sulfur content. Copyright © 2010 John Wiley & Sons, Ltd.
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e190
Inhibitory effect of Ferulic acid against ER stress could suggest the clinical validity of Yokukansan, a Japanese herbal medicine
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e190
Inhibitory effect of Ferulic acid against ER stress could suggest the clinical validity of Yokukansan, a Japanese herbal medicine
- 4 October 2010
- Published by Springer Nature
- p. 83-103
Capillary Electrophoresis and Its Microchip Format for the Analysis of Glycosaminoglycans
- 4 October 2010
- Published by Springer Nature
- p. 83-103
Capillary Electrophoresis and Its Microchip Format for the Analysis of Glycosaminoglycans
- 29 July 2010
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 82 (17) , 7436-7443
Hyphenated Technique for Releasing and MALDI MS Analysis of O-Glycans in Mucin-Type Glycoprotein Samples
We developed an automatic apparatus for the release of O-glycans from mucin-type glycoproteins and proteoglycans (Matsuno, Y.-k.; Yamada, K.; Tanabe, A.; Kinoshita, M.; Maruyama, S.-z.; Osaka, Y.-s.; Masuko, T.; Kakehi, K. Anal. Biochem. 2007, 363, 245−257. Yamada, K.; Hyodo, S.; Matsuno, Y. K.; Kinoshita, M.; Maruyama, S. Z.; Osaka, Y. S.; Casal, E.; Lee, Y. C.; Kakehi, K. Anal. Biochem. 2007, 371, 52−61). The method allows rapid release of O-glycans as the reducing form within 10 min. In the present study, we connected the device to a MALDI-TOF MS spotter and achieved routine analysis of O-glycans in biological samples for clinical use after in situ derivatization of the released O-glycans with phenylhydrazine. We applied the method to the analysis of O-glycans expressed on MKN45 cells derived from human stomach cancer cells and found that MKN45 cells expressed characteristic trisialo-polylactosamine-type glycans as reported previously (Yamada, K.; Kinoshita, M.; Hayakawa, T.; Nakaya, S.; Kakehi, K. J. Proteome Res. 2009, 8, 521−537). We also applied the method to the analysis of O-glycans in serum samples. The present technique is the first attempt to use MS measurement for routine clinical diagnostic works.
- 29 July 2010
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 82 (17) , 7436-7443
Hyphenated Technique for Releasing and MALDI MS Analysis of O-Glycans in Mucin-Type Glycoprotein Samples
We developed an automatic apparatus for the release of O-glycans from mucin-type glycoproteins and proteoglycans (Matsuno, Y.-k.; Yamada, K.; Tanabe, A.; Kinoshita, M.; Maruyama, S.-z.; Osaka, Y.-s.; Masuko, T.; Kakehi, K. Anal. Biochem. 2007, 363, 245−257. Yamada, K.; Hyodo, S.; Matsuno, Y. K.; Kinoshita, M.; Maruyama, S. Z.; Osaka, Y. S.; Casal, E.; Lee, Y. C.; Kakehi, K. Anal. Biochem. 2007, 371, 52−61). The method allows rapid release of O-glycans as the reducing form within 10 min. In the present study, we connected the device to a MALDI-TOF MS spotter and achieved routine analysis of O-glycans in biological samples for clinical use after in situ derivatization of the released O-glycans with phenylhydrazine. We applied the method to the analysis of O-glycans expressed on MKN45 cells derived from human stomach cancer cells and found that MKN45 cells expressed characteristic trisialo-polylactosamine-type glycans as reported previously (Yamada, K.; Kinoshita, M.; Hayakawa, T.; Nakaya, S.; Kakehi, K. J. Proteome Res. 2009, 8, 521−537). We also applied the method to the analysis of O-glycans in serum samples. The present technique is the first attempt to use MS measurement for routine clinical diagnostic works.